<DOC>
	<DOCNO>NCT00421213</DOCNO>
	<brief_summary>The study safety new organic arsenic compound treatment hematological malignancy .</brief_summary>
	<brief_title>Phase II Study ZIO-101 Advanced Blood Bone Marrow Cancers</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Hematologic Neoplasms</mesh_term>
	<mesh_term>Bone Marrow Neoplasms</mesh_term>
	<criteria>Inclusion Criteria 1 . Hodgkin 's nonHodgkin 's Lymphoma . 2 . ≥ 1 prior therapy currently require therapy . 3 . Evaluable disease ( define diseasespecific criterion list Appendix 1 ) 4 . ≥ 18 year age . 5 . ECOG performance score ≤ 2 ( see Appendix 2 ) . 6 . Lifeexpectancy ≥ 2 month . 7 . Written inform consent compliance ZIOPHARM policy Human Investigation Review Committee jurisdiction site . 8 . No anticancer therapy exception hydroxyurea ≤ 3 week Baseline ( Day 1 , Cycle 1 ) . 9 . The following clinical laboratory value &lt; 2 week Baseline : Creatinine ≤ 2X upper limit normal ( ULN ) . Total bilirubin ≤ 2X ULN . Alanine transaminase ( ALT ) aspartate transaminase ( AST ) ≤ 3X ULN . Exclusion Criteria 1 . New York Heart Association ( NYHA ) functional class ≥3 myocardial infarction ( see Appendix ) within 6 month Baseline uncontrolled cardiac arrhythmia asymptomatic atrial fibrillation ; QTc ≥450 msec ; ≥grade2 atrioventricular ( AV ) block leave bundle branch block ( LBBB ) . 2 . Pregnant and/or lactate female . ( Women childbearing age must use effective contraception Screening duration study participation ) . 3 . Uncontrolled infection . 4 . Prior seizure ≥ grade3 CTC v.3 criterion . 5 . Arsenic allergy . 6 . Significant neuropathology , define grade &gt; 2 per CTCAE Version 3.0 . 7 . Confusion dementia . 8 . Prior history neurological deficit ( e.g. , stroke , dementia , ischemia ) potential confound postdose neurological assessment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>APL</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>T-cell Lymphoma</keyword>
	<keyword>Peripheral T-cell Lymphoma</keyword>
</DOC>